Menu Search
Equities

Ion Beam Applications SA

IOBCF:PKL

Ion Beam Applications SA

Actions
  • Price (USD)13.80
  • Today's Change0.00 / 0.00%
  • Shares traded50.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 14:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ion Beam Applications SA (IBA) is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.

  • Revenue in EUR (TTM)465.75m
  • Net income in EUR7.85m
  • Incorporated1986
  • Employees1.84k
  • Location
    Ion Beam Applications SAChemin du Cyclotron 3LOUVAIN-LA-NEUVE 1348BelgiumBEL
  • Phone+32 10475811
  • Fax+32 10475810
  • Websitehttps://iba-worldwide.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		IBAB:BRU since
announced		Transaction
value
Radcal CorpAnnounced08 Feb 202408 Feb 2024Announced39.76%--
Data delayed at least 15 minutes, as of Nov 25 2024 16:35 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.